 This is a Bloomberg Money Minute. Following a wildly lucrative pandemic thanks to its COVID vaccine, Pfizer has been struggling to find its next big thing. This could be it. Today, Pfizer says it's moving forward with tests on a weight loss treatment that, unlike obesity drugs already on the market, doesn't have to be injected. It's a daily pill. Analysts point out that while it's still early, there's a huge potential upside for Pfizer, who shares are up 3%.